Is a 'universal' flu vaccine on the horizon?

A universal flu vaccine may be on the cards.
A universal flu vaccine may be on the cards.

Work is proceeding apace on a "universal" flu vaccine capable of protecting humans from all forms of influenza, researchers report.

A single dose of a synthetic universal flu vaccine called FLU-v appears capable of providing safe long-term protection across a broad spectrum of influenza viruses, a new clinical trial has shown.

FLU-v outperformed a placebo in elevating people's immune response, as measured by a number of different biomarkers related to the immune system, researchers found.

The experimental vaccine now awaits a phase three trial that will test how well it actually protects against the seasonal flu, said lead researcher Olga Pleguezuelos, chief scientific officer at SEEKacure, a London-based pharmaceutical development firm.

Frequent mutation

FLU-v works by targeting parts of the influenza virus that have been shown to evolve the least over time, Pleguezuelos said.

Influenza has sickened as many as 49 million Americans this season and caused up to 620 000 hospitalisations and 52 000 deaths, according to the US Centers for Disease Control and Prevention.

Current annual vaccines trigger the production of antibodies that target proteins found on the surface of the flu virus, Pleguezuelos said.

Unfortunately, the virus regions targeted by those vaccine-produced antibodies tend to mutate frequently, requiring the development of new vaccines to keep up with the ever-changing flu bug.

FLU-v targets proteins that don't vary widely between different strains, reducing the ability of influenza to mask itself from the immune system by evolving into a different form, Pleguezuelos explained.

Researchers used computer algorithms to detect which protein regions in flu were likely to induce a strong immune response, and then analysed how frequently those regions mutate.

Injection site reactions

To strengthen that protection, FLU-v also trains the immune system to target multiple flu proteins that typically aren't under evolutionary pressure to mutate, researchers added.

"FLU-v contains four different components against four different regions of the flu virus, so if one changed, three will still provide efficacy," Pleguezuelos said.

In the latest clinical trial, the researchers found the vaccine promoted antibody responses and immune system changes in 175 healthy adults assigned to receive either the flu shot or a placebo.

Side effects were limited mainly to injection site reactions, the researchers reported in the journal Annals of Internal Medicine.

"In order for the vaccine to reach the market, a phase three trial must be carried out to test efficacy and safety in large number of people," Pleguezuelos said. "This type of study is complex and very costly and we are currently in discussions with regulatory bodies to determine the requirements of such study, and searching for investment and funding."

The results from the latest clinical trial are "very encouraging", said Dr Amesh Adalja, a senior scholar with the Johns Hopkins Center for Health Security in Baltimore.

A major advance

"It illustrates that a candidate universal flu vaccine may be possible and sufficiently immunogenic. It will be important to follow this study up with a phase three study that looks at efficacy of preventing influenza versus just looking at immunogenicity," said Adalja, who was not part of the study.

"A universal flu vaccine would be a major advance and would change the dynamics between humans and the influenza virus in a very positive way," Adalja concluded.

The methods used to develop FLU-v also are being utilised to develop potential vaccines against HIV, mosquito-borne pathogens, hepatitis B and C, and rotavirus, Pleguezuelos said.

The same sort of platform also could be used to develop a coronavirus vaccine, she added.

Image credit: iStock

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
Zama zama crackdown: What are your thoughts on West Village residents taking the law into their own hands?
Please select an option Oops! Something went wrong, please try again later.
Authorities should bring in the army already
10% - 1600 votes
Illegal miners can't be scapegoated for all crime
53% - 8575 votes
What else did we expect without no proper policing
34% - 5425 votes
Vigilante groups are also part of the problem
3% - 516 votes
Rand - Dollar
Rand - Pound
Rand - Euro
Rand - Aus dollar
Rand - Yen
Brent Crude
Top 40
All Share
Resource 10
Industrial 25
Financial 15
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.